(Q55174800)

Vanessa Stadlbauer

6

0 references

Winfried März

9

Winfried März

0 references

Hubert Scharnagl

4

Hubert Scharnagl

0 references

Michael Trauner

10

Michael Trauner

0 references

author name string

Tatjana Stojakovic

1

0 references

Csilla Putz-Bankuti

2

0 references

Günter Fauler

3

0 references

Martin Wagner

5

0 references

Gerald Gurakuqi

7

0 references

Rudolf E. Stauber

Primary biliary cirrhosis

8

0 references

language of work or name

English

0 references

publication date

September 2007

0 references

published in

Hepatology

0 references

volume

46

0 references

issue

3

0 references

page(s)

776-784

0 references

cites work

1 reference

7 January 2021

Cholestatic syndromes

1 reference

7 January 2021

Current management of primary biliary cirrhosis and primary sclerosing cholangitis

1 reference

7 January 2021

Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease

1 reference

7 January 2021

Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid

1 reference

7 January 2021

Characterisation of patients with primary biliary cirrhosis responding to long term ursodeoxycholic acid treatment

1 reference

7 January 2021

Cholesterol-lowering effect of ursodeoxycholic acid in patients with primary biliary cirrhosis

1 reference

7 January 2021

Hypercholesterolaemia is not associated with early atherosclerotic lesions in primary biliary cirrhosis

1 reference

7 January 2021

Hypercholesterolemia in primary biliary cirrhosis: getting to the heart of the matter?

1 reference

7 January 2021

Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis: what is the risk?

1 reference

7 January 2021

Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis

1 reference

7 January 2021

Abnormalities of serum apo A1 containing lipoprotein particles in patients with primary biliary cirrhosis

1 reference

7 January 2021

Hypercholesterolemia in primary biliary cirrhosis is no risk factor for atherosclerosis

1 reference

7 January 2021

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

7 January 2021

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

7 January 2021

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

7 January 2021

Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels

1 reference

7 January 2021

Statins and hepatic steatosis: perspectives from the Dallas Heart Study

1 reference

7 January 2021

Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity

1 reference

7 January 2021

Statin safety: lessons from new drug applications for marketed statins.

1 reference

7 January 2021

Statin safety: a systematic review

1 reference

7 January 2021

Incidence of statin hepatotoxicity in patients with hepatitis C.

1 reference

7 January 2021

Experience with statin use in patients with chronic hepatitis C infection

1 reference

7 January 2021

Simvastatin in primary biliary cirrhosis: effects on serum lipids and distinct disease markers

1 reference

7 January 2021

CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice

1 reference

7 January 2021

Exercising the nuclear option to treat cholestasis: CAR and PXR ligands

1 reference

7 January 2021

Molecular regulation of hepatobiliary transport systems: clinical implications for understanding and treating cholestasis

1 reference

7 January 2021

Enhancement of mdr2 gene transcription mediates the biliary transfer of phosphatidylcholine supplied by an increased biosynthesis in the pravastatin-treated rat

1 reference

7 January 2021

3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) induce hepatic expression of the phospholipid translocase mdr2 in rats

1 reference

7 January 2021

Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial

1 reference

7 January 2021

Oral simvastatin treatment in relapsing-remitting multiple sclerosis

1 reference

7 January 2021

Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans

1 reference

7 January 2021

The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions

1 reference

7 January 2021

Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis

1 reference

7 January 2021

Review article: mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases

1 reference

7 January 2021

Statin induction of liver fatty acid-binding protein (L-FABP) gene expression is peroxisome proliferator-activated receptor-alpha-dependent

1 reference

7 January 2021

Peroxisome proliferator-activated receptor alpha (PPARalpha)-mediated regulation of multidrug resistance 2 (Mdr2) expression and function in mice

1 reference

7 January 2021

Are statins analogues of vitamin D?

1 reference

7 January 2021

Transcriptional activation of p21 by vitamin D(3) or vitamin K(2) leads to differentiation of p53-deficient MG-63 osteosarcoma cells

1 reference

7 January 2021

Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis.

1 reference

7 January 2021

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

7 January 2021

Low-density lipoprotein triglycerides associated with low-grade systemic inflammation, adhesion molecules, and angiographic coronary artery disease: the Ludwigshafen Risk and Cardiovascular Health study

1 reference

7 January 2021